# A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors

> **NCT07473726** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 72 (estimated)

## Conditions studied

- Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** HLX48

## Key facts

- **NCT ID:** NCT07473726
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-17
- **Primary completion:** 2027-03
- **Final completion:** 2028-08
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07473726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07473726, "A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07473726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*